June 2018,
Boston, US

 

Enabling Robust, Safe and Cost-Effective Production
of Highly Potent APIs

The 7th Annual HPAPI Summit will bring together perspectives from every stage of the drug development value chain – from bench to point of outsource – providing you with a unified outlook on the latest developments in highly potent manufacturing.

The increasing commercial potential of highly potent drugs is accompanied by increasingly complicated regulatory requirements, and a continuing lack of effective communication within internal teams and with external contract manufacturers.

In order to address these challenges, this meeting will bring together early-stage process and technical chemists, EHS and toxicology professionals and late-stage outsourcing managers to provide you with comprehensive insights into the highly potent field.

Incorporating insights from Genentech, Pfizer, SafeBridge, Seattle Genetics and Takeda, this three day meeting will include the very latest insights into process development and scale-up, EHS and occupational toxicology, innovative containment and cleaning solutions, and optimizing outsourcing and tech transfer strategies.

Join your colleagues in 2018 and learn how to produce highly potent APIs robustly, safely and cost-effectively.

“This conference is clearly the leader in the HPAPI arena. Without a doubt, I will be returning!”

Pfizer

"This conference can serve as both an incubator and catalyst to educate and harmonize across the industry."

Seattle Genetics

2017 Attendees Included:
2017 Attendees Update